$FBIO

Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics' $205 Million Series A Financing

Dotinurad is a next-generation URAT1 inhibitor in two Phase 3 clinical trials with potential for best-in-class safety and efficacy ...

Original reporting
GlobeNewswire · Fortress Biotech, Inc.
Published Oct 1, 2025, 12:05 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Oct 1, 2025, 1:00 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics' $205 Million Series A Financing — source image
Decision brief

The 30-second read

$FBIOBullishMed
01

Why it matters

This funding boosts Fortress Biotech's financial position and validates its clinical pipeline, potentially leading to stock appreciation.

02

Market read

The news is highly relevant for biotech investors, indicating strong sector momentum and promising clinical developments.

03

What to watch

Regulatory hurdles or market competition could diminish the positive impact of the funding announcement.

Timing: Immediate, as the news is recent and relevant for upcoming trading sessions.

Background

Fortress Biotech's subsidiary, Urica Therapeutics, announced a significant Series A financing for Crystalys Therapeutics, supporting the development of Dotinurad, a next-generation URAT1 inhibitor in Phase 3 trials.

Company-level read

Ticker impact

$FBIOBullishHigh confidence
Context

Directly related, as Fortress Biotech is the parent company involved in the financing announcement.

Expected impact

Potential short-term increase in FBIO stock price, with a possibility of sustained growth if clinical trials yield favorable results.

Evidence & confidence

The substantial Series A funding and clinical trial updates are strong positive indicators for Fortress Biotech's valuation.

Market effects

Strengthens biotech sector sentiment, especially for companies involved in clinical trials and biotech financing.

Primarily US-focused, with potential ripple effects in global biotech markets.

Moderate, as biotech funding trends influence international investor confidence.

Counterpoint

The funding may already be priced in, and any delays or setbacks in clinical trials could lead to a sharp decline in stock prices.

Key entities

  • Fortress Biotech

    A biotech company focusing on innovative therapies.

  • Crystalys Therapeutics

    A subsidiary of Fortress Biotech developing Dotinurad.

  • Dotinurad

    A URAT1 inhibitor in Phase 3 clinical trials.

Related articles

$AALMed

American Airlines Management Shake-up Aims To Close Leverage With Competitors and Improve Service

American Airlines began a senior leadership reorganization, according to an Aug. 10 letter from CEO Robert Isom. Several executives are resigning or retiring, while roles expand for communications and customer service. The changes aim to improve operations and returns and close a profit gap versus Delta and United. In Q2 2026, American reported $71M net income versus $805M at United and $1.6B at Delta.

$RIOMed

Federal politics live: $2.5bn Tomago bailout 'vital' to protect Australia's largest aluminium smelter, minister says

Australia’s federal and NSW governments will announce a $2.5 billion, 10-year bailout for Tomago Aluminium, aimed at securing power supply and decarbonisation. Industry Minister Tim Ayres said the deal includes profit sharing with the Commonwealth when aluminium prices are high and $100 million for decarbonisation and demand-response. Separately, Labor will introduce a revised News Bargaining Incentive bill requiring big tech to make at least eight content deals.

$LMTMedAI 8/10

Lockheed Martin wins $211 million UAE defense contract

Lockheed Martin (NYSE:LMT) said the U.S. Missile Defense Agency awarded a $211.4 million contract modification to manufacture THAAD missile defense launchers for the United Arab Emirates. The change raises the 2019 contract total to $1.05 billion, with production from Aug 2026 to Jan 2031 under Foreign Military Sales funding.

$INTCMed

5 Things to Know Before the Stock Market Opens on Tuesday

Stock futures edged higher after Monday’s decline as investors awaited AI-related earnings. Oil prices wavered after hopes for an Iran deal faded. Intel (INTC) raised its stock offering to $20B, pricing about 210.53M shares at $95. Riot Platforms (RIOT) jumped after results and a $9.1B, 20-year Anthropic compute deal. Several AI-linked earnings were scheduled.

$STEMMed

Stem, Inc.: Stem's PowerTrack EMS Enables Hybridization of Two Operating Utility-Scale Solar Plants in Hungary

Stem, Inc. (NYSE: STEM) said Solarmarkt Group, with EPC partner Pannonwatt, selected Stem’s PowerTrack Energy Management System to hybridize two operating utility-scale solar plants in Hungary. The five-year agreement covers adding 40 MW/80 MWh batteries to each site, targeting commercial operation by Sept 2026 and participation in Hungary’s aFRR market.